Sphingomonas paucimobilis analysis of clinical susceptibility factors and drug treatment strategy

doi:10.12092/j.issn.1009-2501.2019.08.016

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2019, Vol. 24 ›› Issue (8): 944-947.doi: 10.12092/j.issn.1009-2501.2019.08.016

Previous Articles Next Articles

Sphingomonas paucimobilis analysis of clinical susceptibility factors and drug treatment strategy

WANG Huan^1,2, YUAN Jingjing ^2,3, QU Jian², LU Qiong ²

¹ Department of Pharmacy, Zhengzhou Second Hospital, Zhengzhou 450000, Henan, China; ²Department of Pharmacy,Second Xiangya Hospital, Central South University, Changsha 410011, Hunan,China;3Department of Pharmacy, Hunan Wantwant Hospital, Changsha 410000, Hunan, China

Received:2019-01-09 Revised:2019-07-29 Online:2019-08-26 Published:2019-08-30

Abstract

Abstract:

AIM: To investigate the susceptibility factors and drug resistance of Sphingomonas paucimobilis in hospital. METHODS: A retrospective analysis of 7 etiology examinations revealed underlying disease, specimen source, antibiotic history, and drug susceptibility testing in patients with Sphingomonas sphaeroides.RESULTS:Sphingomonas sphaeroides had better sensitivity to carbapenems and compound neostigmine, certain sensitivity to aminoglycosides and fluoroquinolones, and poor sensitivity to aztreonam and third generation cephalospores.CONCLUSION: In addition to the previously reported immunodeficiency, pulmonary infection, and broad-spectrum antibiotic history, the predisposing factors of Sphingomonas sphingia may also have factors such as hypoproteinemia and history of hepatitis B virus. Therapeutic medication should avoid the choice of aztreonam and third-generation cephalosporins.

Key words: sphingomonas paucimobilis, susceptibility factor, drug selection

CLC Number:

R378

WANG Huan, YUAN Jingjing, QU Jian, LU Qiong. Sphingomonas paucimobilis analysis of clinical susceptibility factors and drug treatment strategy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 944-947.

References

［1］Kuo I, Lu PL, Lin WR, et al. Sphingomonas paucimobilis bacteraemia and septic arthritis in a diabetic patient presenting with septic pulmonary emboli［J］.J Med Microbiol, 2009, 58(9):1259-1263.
［2］Bolen RD, Palavecino E, Gomadam A, et al. Sphingomonas paucimobilis meningitis and ventriculitis in an immunocompromised host［J］. J Neurol Sci, 2015, 359(1/2):18-20.
［3］El Beaino M,Fares J,Malek A,et al.Sphingomonas paucimobilis-related bone and soft-tissue infections: A systematic review［J］.Int J Infect Dis，2018，77:68-73.
［4］Kawahara K,Kuraishi H,Zhringer U.Chemical structure and function of glycosphingolipids of Sphingomonas spp and their distribution among members of the alpha-4 subclass of Proteobacteria［J］.J Ind Microbiol Biotechnol，1999,23(4/5):408-413.
［5］Pinyakong O, Habe H, Omori T.The unique aromatic catabolic genes in sphingomonads degrading polycyclic aromatic hydrocarbons (PAHs)［J］.J Gen Appl Microbiol，2003，49(1):1-19.
［6］Bayram N, Devrim I, Apa H, et al. Sphingomonas paucimobilis infections in children: 24 case reports［J］. Mediterr J Hematol Infect Dis，2013，5(1):e2013040.
［7］Benevides GN, Hein N, Lo DS,et al.Otomastoiditis caused by Sphingomonas paucimobilis: case report and literature review［J］.Autops Case Rep，2014，4(3):13-20.
［8］华春珍, 娄国强, Richard M. 少动鞘氨醇单胞菌及其感染的临床特点和治疗［J］.中华传染病杂志, 2012, 30(12):751-754.
［9］Hardjo Lugito NP, Cucunawangsih, Kurniawan A.A lethal case of sphingomonas paucimobilis bacteremia in an immunocompromised patient［J］. Case Rep Infect Dis，2016, 2016:3294639.
［10］Lin JN, Lai CH, Chen YH , et al. Sphingomonas paucimobilis Bacteremia in Humans: 16 Case Reports and a Literature Review［J］. J Microbiol Immunol Infect, 2010, 43(1):35-42.
［11］来汉江, 杨莉俊, 周鸿亮, 等.116例少动鞘氨醇单胞菌的医院感染及耐药特点［J］.中华医院感染学杂志, 2010, 20(4):581-583.
［12］Vincent JL,Dubois MJ,NaVickis RJ,et al.Hypoalbuminemia in acute illness: is there a rationale for intervention?A meta-analysis of cohort studies and controlled trials［J］.Ann Surg，2003，237（3）:319-334.
［13］Li F, Yuan MZ, Wang L, et al.Characteristics and prognosis of pulmonary infection in patients with neurologic disease and hypoproteinemia［J］. Expert Rev Anti Infect Ther, 2015, 13(4):521-526.
［14］殷稼雯,王进科,殷国庆.HBV感染免疫学应答的新进展和新观点［J］.中国肝脏病杂志(电子版),2016,8(3):34-37.
［15］Sullivan A, Edlund C, Nord CE.Effect of antimicrobial agents on the ecological balance of human microflora［J］.Lancet Infect Dis，2012，18(2):249-253.
［16］Kuo I, Lu PL, Lin WR, et al. Sphingomonas paucimobilis bacteraemia and septic arthritis in a diabetic patient presenting with septic pulmonary emboli［J］.J Med Microbiol，2009, 58(9):1259-1263.
［17］Corkill JE, Hart CA, Mclennan AG, et al. Characterization of a beta-lactamase produced by Pseudomonas paucimobilis［J］. J Gen Microbiol, 1991, 137(6):1425-1429.
［18］Leekha S, Terrell CL, Edson RS.General principles of antimicrobial therapy［J］. Mayo Clin Proc，2011，86(2):156-167.

[1]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[2]	FANG Qing, OU-YANG Dongsheng. Trimethylamine N-oxide and inflammatory disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 318-326.
[3]	LI Nai-jing, LI Yan, PAN Zuo-dong, HE Ping, LI Sheng-qi. Determination of the AmpC and ESBL produced in the biofilm of klebsiella pneumoniae [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(4): 384-387.

Sphingomonas paucimobilis analysis of clinical susceptibility factors and drug treatment strategy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments